Investigating the Structured Use of Ultrasound Scanning for Fetal Growth

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

56000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2029-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015).

Therefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing.

However, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015).

Oxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention.

It has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting.

The principles of the pathway are

1. A universal routine scan at 36 weeks gestation.
2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation.
3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR).

The clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal / reference ranges for ultrasound values.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction

NCT06893926

s100b Hypoxia-Ischemia, Brain Fetal Growth Restriction (FGR)

RECRUITING

Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction

NCT05023161

Fetal Growth Retardation

RECRUITING

EVERREST Developing a Therapy for Fetal Growth Restriction

NCT02097667

Fetal Growth Retardation

COMPLETED

Saccadic Reaction Time and Preterm Pre-eclampsia

NCT02613793

Pre-eclampsia

TERMINATED

Placental Imaging Techniques

NCT06861309

Fetal Growth Restriction (FGR) Placental Insufficiency Preeclampsia +5 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is no requirement for patient participation in this study. All data collected and analysed is routinely collected clinical data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stillbirth Fetal Death Fetal Growth Retardation Small for Gestational Age Fetal Growth Restriction Perinatal Death Intrauterine Growth Restriction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.
* If intrapartum care takes place outside of the OUHFT.

Minimum Eligible Age

16 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes